Capital Advisors Inc. OK Has $581,000 Holdings in OPKO Health, Inc. (NASDAQ:OPK)

Capital Advisors Inc. OK lifted its position in OPKO Health, Inc. (NASDAQ:OPK - Free Report) by 133.3% in the 1st quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 350,000 shares of the biotechnology company's stock after acquiring an additional 200,000 shares during the quarter. Capital Advisors Inc. OK owned approximately 0.05% of OPKO Health worth $581,000 as of its most recent filing with the SEC.

A number of other hedge funds and other institutional investors have also recently added to or reduced their stakes in OPK. Wealth Enhancement Advisory Services LLC boosted its stake in shares of OPKO Health by 75.3% during the 4th quarter. Wealth Enhancement Advisory Services LLC now owns 28,908 shares of the biotechnology company's stock valued at $42,000 after buying an additional 12,417 shares during the period. Pallas Capital Advisors LLC acquired a new position in OPKO Health during the first quarter worth $43,000. Cibc World Markets Corp bought a new stake in shares of OPKO Health during the 4th quarter worth about $45,000. Zacks Investment Management acquired a new stake in OPKO Health in the 4th quarter worth approximately $49,000. Finally, Mercer Global Advisors Inc. ADV grew its holdings in OPKO Health by 105.6% during the fourth quarter. Mercer Global Advisors Inc. ADV now owns 43,167 shares of the biotechnology company's stock valued at $63,000 after purchasing an additional 22,167 shares during the last quarter. Institutional investors and hedge funds own 64.63% of the company's stock.

OPKO Health Stock Performance

Shares of NASDAQ OPK traded down $0.03 during trading hours on Thursday, reaching $1.36. The stock had a trading volume of 541,676 shares, compared to its average volume of 3,870,448. The company has a market cap of $1.07 billion, a price-to-earnings ratio of -19.35 and a beta of 1.34. OPKO Health, Inc. has a twelve month low of $1.21 and a twelve month high of $2.04. The business's fifty day moving average is $1.32 and its two-hundred day moving average is $1.49. The company has a debt-to-equity ratio of 0.25, a current ratio of 2.49 and a quick ratio of 2.28.

OPKO Health (NASDAQ:OPK - Get Free Report) last issued its earnings results on Wednesday, April 30th. The biotechnology company reported ($0.10) earnings per share for the quarter, missing the consensus estimate of ($0.07) by ($0.03). OPKO Health had a negative net margin of 5.66% and a negative return on equity of 2.85%. The business had revenue of $149.90 million for the quarter, compared to analyst estimates of $163.13 million. During the same quarter last year, the firm posted ($0.12) earnings per share. OPKO Health's revenue was down 13.7% on a year-over-year basis. As a group, research analysts expect that OPKO Health, Inc. will post -0.25 EPS for the current year.

Wall Street Analyst Weigh In

Several brokerages recently commented on OPK. HC Wainwright reiterated a "buy" rating and issued a $3.00 target price on shares of OPKO Health in a report on Monday, April 7th. Wall Street Zen downgraded OPKO Health from a "hold" rating to a "sell" rating in a research note on Monday, May 5th. JPMorgan Chase & Co. initiated coverage on OPKO Health in a research report on Friday, April 25th. They issued a "neutral" rating on the stock. LADENBURG THALM/SH SH raised OPKO Health to a "strong-buy" rating in a research report on Tuesday. Finally, Barrington Research reaffirmed an "outperform" rating and set a $2.25 target price on shares of OPKO Health in a research report on Thursday, May 1st. One research analyst has rated the stock with a sell rating, one has assigned a hold rating, three have given a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat, the company has an average rating of "Moderate Buy" and a consensus target price of $2.75.

About OPKO Health

OPKO Health, Inc, a healthcare company, engages in the diagnostics and pharmaceuticals businesses in the United States, Ireland, Chile, Spain, Israel, Mexico, and internationally. The company's Diagnostics segment operates BioReference Laboratories that offers laboratory testing services for the detection, diagnosis, evaluation, monitoring, and treatment of diseases, including esoteric testing, molecular diagnostics, anatomical pathology, genetics, women's health, and correctional healthcare to physician offices, clinics, hospitals, employers, and governmental units; and 4Kscore prostate cancer test.